The pregnancy outcome prediction (POP) study: Investigating the relationship between serial prenatal ultrasonography, biomarkers, placental phenotype and adverse pregnancy outcomes

Francesca Gaccioli, Susanne Lager, Ulla Sovio, D. Stephen Charnock-Jones, Gordon C.S. Smith

1. Introduction

1.1. Clinical context

Pregnancies complicated by preeclampsia (PE) and fetal growth restriction (FGR) are associated with an increased risk of maternal and perinatal morbidity, as well as mortality [1,2]. FGR is estimated to be the underlying cause in 30–50% cases of stillbirths [3]. Moreover, FGR and PE are defined as placentally-related complications in a large proportion of cases, as they are often characterised by defective placental development (e.g. inadequate remodelling of maternal spiral arteries and altered utero-placental blood perfusion) [4]. Therefore placental dysfunction is one of the underlying factors which contribute to PE and FGR, and concomitantly stillbirth. This offers a great opportunity to identify women at risk using biomarkers reflecting defective placentation.

Currently, antenatal care of first pregnancies in UK involves 10 routine midwife visits (Fig. 1A). Such high intensity reflects a poor discrimination of risk: most severe adverse outcomes in first pregnancies occur to women who are deemed to be “low risk” at booking. Moreover, the primary screening method for women is for the midwife to measure symphyseal-fundal height with a tape measure, check blood pressure and test urine for proteinuria. The only widely used biomarker for placentally-related complications (low first trimester PAPP-A, see below) was the result of secondary analysis of data collected to identify new methods of screening for Down’s syndrome rather than as a purposeful search for screening tests for abnormal placentation. Development of improved methods for population screening requires better mechanistic understanding of the pathways leading to placentally-related complications of human pregnancy. This is in addition to a need for identification of biomarkers which reflect the underlying pathology, while predicting associated disease with high sensitivity and specificity. In this paper, we outline some of the challenges and opportunities in this area. Furthermore, we illustrate how some of these can be addressed in research studies using the example of the Pregnancy Outcome Prediction (POP) study, a prospective cohort study conducted in Cambridge, UK.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
targeting of resources in a more cost-effective and clinically effective manner for high risk women. We are attempting to address this goal by conducting a prospective cohort study of unselected nulliparous women, focusing on serial ultrasonography measurements and collection of biological samples. In this article we outline rationale and conduct of the study, while addressing some general points for researchers considering similar studies.

1.2. Clinical screening using placental assessment

Fetal growth is evaluated using ultrasonographic fetal biometry and calculation of estimated fetal weight (EFW). Placental function

Fig. 1. A) Standard antenatal care for nulliparous women in the UK, including 10 routine midwife visits and additional visits for women delivering after 40wGA. B) Flow chart of the POP study.
is assessed using Doppler flow velocimetry of the maternal uterine and fetal umbilical arteries. Flow resistance of the uterine artery decreases during the first half of pregnancy due to invasion of the placental vessels by the trophoblast cells. Persistence of high resistance patterns of flow in both the uterine and umbilical artery in mid-gestation and in the third trimester of pregnancy has been associated with altered placental function and structure as well as increased risk of obstetric complications [5–8]. Currently, these methods are applied selectively to women with pre-existing risk factors or acquired complications of pregnancy. However, the sensitivity of selective use of ultrasonography for detecting small babies is poor, in the region of 20–25% [9,10]. The obvious alternative, universal ultrasonography, is not recommended: systematic reviews have failed to show an improvement in clinical outcome with universal ultrasonography in late pregnancy [11]. However, the apparent absence of benefit may be due methodological weaknesses [12], such as study heterogeneity, failure to design an effective interventional strategy after the identification of the screen-positive cases, and lack of statistical power [13]. Although there is currently strong case for population-based screening using universal ultrasound, this has been identified as a high priority for further research [14].

In the UK, clinical guidelines recommend increased surveillance of women having low first trimester levels of the placenta-derived protein PAPP-A [15,16]. However, this association was found following secondary analyses of Down’s syndrome screening studies, which demonstrated that low maternal levels of PAPP-A in the first trimester were associated with PE, FGR and stillbirth risk [17,18]. More recently other biochemical biomarkers related to angiogenesis (i.e., Placental Growth Factor (PIGF), solute fms-like tyrosine kinase 1 (sFlt-1), soluble Endoglin (sEng)) have been proposed as potential screening tests for PE and FGR [19–22]. Although potentially promising, their clinical usefulness has been shown to be modest in several studies [19,23,24]. Their diagnostic effectiveness as a screening test remains to be properly assessed in low risk populations, close to term (when an effective intervention is available, i.e. delivery of the baby), in association with different phenotypes of the disease (especially in pregnancies with small babies), and in combination with other biomarkers.

2. Designing a study for identification of novel screening approaches

2.1. Overview, aims and design of POP study

The Pregnancy Outcome Prediction (POP) study is a prospective cohort study of nulliparous women attending the Rosie Hospital (Cambridge, UK) for their dating ultrasound scan [25]. The study included 4512 women with a viable singleton pregnancy; study participants provided written informed consent and were recruited between January 2008 and July 2012 (Fig. 1B) [10]. The rationale behind recruiting only nulliparous women is that they have a higher absolute risk of developing pregnancy complications compared to multiparous women [26,27]. Furthermore, they lack previous pregnancy outcome information which is an important risk indicator for subsequent pregnancies [28,29].

The POP study aimed both at evaluating performance of known biomarkers and serial ultrasonography in assessing maternal and fetal well-being, as well as identifying novel biomarkers. The study is sufficiently large to be powered for relatively uncommon adverse pregnancy outcomes (Table 1) [25]. Women attended four study visits scheduled every 8 weeks, starting with the first trimester. Participants had blood taken during the dating/recruitment visit (at approximately 12 weeks gestation (wkGA)), as well as at three subsequent visits (at ~20wkGA, ~28wkGA and ~36wkGA). On each of these three visits research ultrasound scans were also performed to assess fetal biometry, amniotic fluid index, uterine and umbilical uterine artery Doppler flow velocimetry and placental maturity. Serial measurements and sampling offer the chance to monitor the parameters of interest throughout gestation, and changes across pregnancy have been suggested to have more predictive power than single snapshots in time [30,31]. The final evaluation at 36wkGA was intended as a means to screen for risk of complications at term, when effective intervention to prevent placenta-related complications of pregnancy is available (i.e., early delivery). The timing of this visit was informed by previous analyses demonstrating that tests of placental dysfunction (i.e., biochemical and ultrasonic screening) have a better predictive value when performed close to disease onset [32]. Patients and clinicians were blinded to these ultrasonography results, unless major congenital abnormalities, placenta praevia, severe oligohydramnios or breech presentation (36wkGA only) were detected. At the 20wkGA visit, a questionnaire was completed to retrieve the patient’s demographic data and medical history. During the same visit a DNA sample of the partner and measurements of the partner’s height/weight were collected. After delivery, biopsies of the placenta, placental

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Numbers and rates of adverse outcomes of women participating in the POP study.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome</td>
<td>N – 4212</td>
</tr>
<tr>
<td>GDM</td>
<td>192 (4.6)</td>
</tr>
<tr>
<td>Missing</td>
<td>6 (0.1)</td>
</tr>
<tr>
<td>Pre-eclampsia/hypertension</td>
<td></td>
</tr>
<tr>
<td>De novo PE, not severe</td>
<td>53 (1.3)</td>
</tr>
<tr>
<td>De novo PE, severe</td>
<td>93 (2.2)</td>
</tr>
<tr>
<td>Superimposed PE, not severe</td>
<td>85 (2.0)</td>
</tr>
<tr>
<td>Superimposed PE, severe</td>
<td>42 (1.0)</td>
</tr>
<tr>
<td>GH, not severe</td>
<td>62 (1.5)</td>
</tr>
<tr>
<td>GH, severe</td>
<td>23 (0.6)</td>
</tr>
<tr>
<td>Essential HT</td>
<td>99 (2.4)</td>
</tr>
<tr>
<td>Missing</td>
<td>5 (0.1)</td>
</tr>
<tr>
<td>sPTD</td>
<td>113 (2.7)</td>
</tr>
<tr>
<td>Missing</td>
<td>41 (1.0)</td>
</tr>
<tr>
<td>Induction of labour</td>
<td>1355 (32)</td>
</tr>
<tr>
<td>Mode of delivery</td>
<td></td>
</tr>
<tr>
<td>Spontaneous vaginal</td>
<td>2051 (49)</td>
</tr>
<tr>
<td>Assisted vaginal</td>
<td>992 (24)</td>
</tr>
<tr>
<td>Intrapartum caesarean section</td>
<td>726 (17)</td>
</tr>
<tr>
<td>Pre-labour caesarean section</td>
<td>424 (10)</td>
</tr>
<tr>
<td>Missing</td>
<td>19 (0.5)</td>
</tr>
<tr>
<td>Outcome of birth</td>
<td></td>
</tr>
<tr>
<td>Livebirth</td>
<td>4161 (99)</td>
</tr>
<tr>
<td>Miscarriage (pre-viable &lt;24wks)</td>
<td>13 (0.3)</td>
</tr>
<tr>
<td>Termination of pregnancy &lt;24wks</td>
<td>17 (0.4)</td>
</tr>
<tr>
<td>Termination of pregnancy &gt;24wks</td>
<td>11 (0.3)</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>11 (0.3)</td>
</tr>
<tr>
<td>Neonatal death</td>
<td>6 (0.1)</td>
</tr>
<tr>
<td>Missing</td>
<td>3 (0.1)</td>
</tr>
<tr>
<td>Any neonatal morbidity</td>
<td></td>
</tr>
<tr>
<td>292 (6.9)</td>
<td></td>
</tr>
<tr>
<td>Metabolic acidosis</td>
<td>45 (1.1)</td>
</tr>
<tr>
<td>5-min Apgar &lt;7</td>
<td>42 (1.0)</td>
</tr>
<tr>
<td>Neonatal unit admission</td>
<td>240 (5.7)</td>
</tr>
<tr>
<td>Severe adverse perinatal outcome</td>
<td>39 (0.9)</td>
</tr>
</tbody>
</table>

Abbreviations: GDM – gestational diabetes mellitus, PE – preeclampsia, GH – gestational hypertension, essential HT – essential hypertension, sPTD – spontaneous preterm delivery (23-36 completed weeks, <23 weeks included in the missing category), Data were obtained from examination of the clinical case records and by linkage to the hospital’s electronic databases and are expressed as n (%). Any neonatal morbidity was defined as one or more of the following: delivery with metabolic acidosis (cord blood pH <7.1 and base deficit >10mmol/L), a 5-minute Apgar score <7, or admission to neonatal unit at term (within 48 hours from birth for at least 48 hours). Severe adverse perinatal outcome was defined as one or more of the following: stillbirth (not due to congenital anomaly), neonatal death at term (not due to congenital anomaly), hypoxic ischaemic encephalopathy at term, use of inotropes at term, mechanical ventilation at term, severe metabolic acidosis at term (defined as pH <7.0 and base deficit >12 mmol/L). For characteristics that have no “missing” category, data were 100% complete.

Please cite this article in press as: F. Gaccioli, et al., The pregnancy outcome prediction (POP) study: Investigating the relationship between serial prenatal ultrasonography, biomarkers, placental phenotype and adverse pregnancy outcomes, Placenta (2016), http://dx.doi.org/10.1016/j.placenta.2016.10.011
membranes, umbilical cord, and cord blood were collected (see below).

A further point of note is that the population in the POP study is low risk and homogeneous, from a demographic and socio-economic perspective (Table 2). The low risk nature of the cohort is an important study strength from the perspective of both evaluating screening tests and identifying novel mechanisms/biomarkers of placental dysfunction. It is well-recognized that studies can overestimate the positive predictive value of a screening test by extrapolating results of selected and high risk cohorts to the general population (called the “spectrum effect”) [33]. Moreover, when studying mechanisms it would clearly be problematic if cases were largely derived from a population of different ethnicity and socio-economic status than controls. This is a potential hazard as many placenta-related complications of pregnancy are more common in minority and socio-economically deprived communities.

2.2. Other prospective cohort studies: NuMoMs2b and SCOPE

Other prospective cohort studies recruiting nulliparous women with singleton pregnancies have been conducted, such as the Nulliparous Pregnancy Outcome study (NuMoMs2b) and the Screening for Pregnancy Endpoints (SCOPE) [34,35]. Approximately 10,000 women were recruited in the NuMoMs2b study in multiple centres across the United States. The SCOPE study was a multicentre cohort study including about 5500 women in Australia, Ireland, New Zealand, and the United Kingdom. As in the POP study, women enrolled in the SCOPE and NuMoMs2b studies were recruited in early pregnancy, at ~12-18wkGA. Although the cohort populations are similar in the three studies, there are some important differences. For instance, in the SCOPE and NuMoMs2b studies the last study visits were conducted at ~24wkGA and ~28wkGA, respectively, therefore excluding a collection point close to term which may be important for predicting adverse pregnancy outcome [32]. Additionally, placental samples were collected from a small percentage of the participants in the NuMoMs2b study and the SCOPE study did not include routine placenta collection. Finally, all three studies performed research ultrasound examinations. However, the results of these scans were reported in both SCOPE and NuMoMs2b, whereas in POPs the results were blinded in >94% of cases. One of the criteria for a Level 1 study of diagnostic effectiveness is blinding results from the screening test being evaluated, in this case serial universal ultrasonography [10].

2.3. Multiple methodological approaches around a single study

Since the POP study is a large prospective study, it offers the possibility of analysing parameters and values measured at a specific gestational, but also changes over time. This has been suggested to be useful in the search of biomarkers for pregnancy complications [30,31]. Moreover, multiple approaches are available for sample and data analysis, which can be carried out on the whole study cohort or subsets of participants. Alternative methodological approaches can be used, such as case-cohort study and nested, matched case-control study.

2.3.1. Prospective cohort study

When using this type of analysis, data available from all the study participants (such as ultrasound scan results and maternal demographic information) are employed to calculate incidence rates, relative risks, and confidence intervals [36]. This approach has been used to compare the detection rates of small for gestational age (SGA) infants using selective and universal ultrasound examinations. However, the results of these scans were reported in both SCOPE and NuMoMs2b, whereas in POPs the results were blinded in >94% of cases. One of the criteria for a Level 1 study of diagnostic effectiveness is blinding results from the screening test being evaluated, in this case serial universal ultrasonography [10].

2.3.2. Case-cohort study

A case-cohort methodological approach utilises all cases (of differing types; i.e., PE, gestational diabetes, FGR) within the cohort and a randomly selected sub-cohort as control group [37]. Thus for...
all differing adverse outcomes there is one common group of controls. Such an approach may be advantageous if expensive or labour intensive assays are being performed, since it reduces the number of samples processed while still achieving a similar precision compared to using measurements from the whole cohort. Similar to whole cohort analysis, calculation of relative risks is possible using a case-cohort methodological approach. This design is currently being used in the POP study to investigate metabolomic markers of a range of pregnancy outcomes.

2.3.3. Nested matched case-control study

With a nested case-control methodological approach, identified cases within a larger cohort are selected and matched one-to-one with healthy controls [36]. Cases are paired with controls based upon key characteristics (e.g., maternal body mass index (BMI), gestational age (GA), and fetal sex) and statistical comparisons are based on paired methods (e.g., paired t-test for continuous variables and the McNemar test for dichotomous variables). Therefore, potential confounders are adjusted through matching. The nested case-control approach is particularly useful for molecular studies where methodologies are very expensive and/or labour intensive, as well as when adjustments using multivariate statistical models are not approvable. In the POP study there are currently several projects with this design, based on Next Generation Sequencing (NGS) and histological examinations of placental specimens (discussed below).

2.3.4. Synergies between study designs

A key element of the POP study is that data used for one element of the analysis can strengthen other aspects of the analysis. For example, the results of uterine and umbilical Doppler flow velocimetry were employed in the analysis of universal ultrasound as a screening test for SGA and FGR. The same data then allows SGA infants to be phenotyped in greater detail. We can show that better phenotyping of SGA cases results in a much larger number of positive results in RNA-Seq analysis (see below). We thereby conclude that heterogeneity within groups with apparently similar outcomes can mask differences between cases and controls.

3. Current findings

Several projects planned with samples from the POP study are currently ongoing: the analysis of clinical records and outcome data parallels and complements the wet lab work.

3.1. Ultrasonographic fetal biometry

Historically, fetal biometry measurements had a particular focus upon the identification of SGA babies [38]. As described above, clinically indicated ultrasonography in the third trimester has a low sensitivity (20–25%) for detecting SGA babies [9,10]. We demonstrated that screening of nulliparous, low risk women with universal third trimester fetal biometry triples the detection of SGA infants [10]. Moreover, analysis of the abdominal circumference (AC) growth velocity was the most effective method for discriminating between healthy SGA infants and those with FGR.

Other recent analyses of the POP study cohort have yielded insights from serial assessment of fetal biometry. We have reported that reduced fetal growth velocity of the femur between 20 and 28wkGA was associated with a ~2.5 fold increased risk of spontaneous preterm birth [39]. We have also reported associations with excessive growth. We found that maternal diagnosis of gestational diabetes mellitus (GDM) at or after 28wkGA was preceded by excessive AC growth between 20 and 28wkGA; GDM effects on fetal growth were additive with the effects of maternal obesity [40]. Given that biochemical testing for CDM typically takes place at around 28wkGA, data indicate that earlier screening and intervention may result in better control of excessive fetal growth.

3.2. Automated immunoassay analysis of maternal serum samples

Although maternal blood is an easily accessible and attractive resource of potential biomarkers for pregnancy complications, the factors studied so far revealed low predictive power for PE and FGR. The maternal serum samples collected in the POP study at ~12wkGA, ~20wkGA, ~28wkGA and ~36wkGA have been analysed to determine whether combination of universal ultrasound and previously described placental biomarkers may improve identification of pregnancies at increased risk of adverse outcome. A total of 15,874 serum samples from the 4212 women who completed the study have been analysed using clinical grade Roche Elecsys immunoassays on an electro-chemiluminescence platform (cobas e411 analyzer, Roche Diagnostics, Mannheim, Germany). We analysed levels of proteins where there is a clinical grade assay available and where previous studies have shown associations with placental function: alpha fetoprotein (AFP), chorionic gonadotropin (hCG), PAPP-A, PIGF, and sFlt-1. All the samples have been processed and the analysis in relation to the pregnancy outcomes is currently ongoing. Interestingly, a plot of the raw data demonstrates that the 5 proteins show different patterns of change in relation to gestational age, suggesting that each reports different aspects of placental function (Fig. 2).

3.3. Placental morphometry and histology

A series of photographs were taken of maternal and fetal sides of the whole placenta, as well as 1 cm thick strips (Fig. 3) [https://www.obgyn.cam.ac.uk/research/pops-2/]. Using these images, the relation between prenatal ultrasonic measurements and postnatal placental morphometry has been investigated [6]. We demonstrated that reduced placental surface area is associated with high resistance uterine artery Doppler at 20wkGA, while lower placental weight is associated with high resistance umbilical Doppler at 36wkGA. Furthermore, reduced placental surface area and placental weight are associated with reduced fetal growth velocity.

Several ongoing projects are based upon histopathological analysis of placental biopsies. For example, we are currently studying matched case-control pairs, focusing on both PE and FGR. 3420 biopsies from 855 placentas have been fixed and cut for microscopy (Fig. 3). Each biopsy is analysed using nine stains (hematoxylin and eosin (H&E), 5-hydroxymethylcytosine, CD14, CD3, CD31, CD4, CD79a, CD8, and neutrophil elastase), for a total of 30,780 biopsies stained using the fully automated platform BOND-III (Leica Biosystems). High-resolution images are generated by an Aperio AT2 scanner (Leica Biosystems). These are analysed quantitatively and blind to clinical outcome using a Visiopharm computer assisted stereology toolbox and image analysis. H&E sections are also being reported by two perinatal pathologists who are blind to outcome.

3.4. Next Generation Sequencing (NGS)

NGS is one of the major methods of analysis employed in studying placental biopsies, with a focus both on the transcriptome and the epigenome (small RNAs, DNA methylation and histone modifications). These analyses have the following aims: (i) understanding the mechanisms leading to placenta-related complications; (ii) studying the association between pregnancy complications and the presence of infectious agents in the placenta, and (iii) identifying of novel biomarkers that can be evaluated in
Fig. 2. Biomarkers measured in maternal serum samples from women completing the study (n = 4212). A) AFP, B) hCG, C) PAPP-A, D) PI GF, E) sFlt-1, and F) the ratio of sFlt-1/PI GF were measured in serum samples collected at ~12wkGA (n = 4078), ~20wkGA (n = 4021), ~28wkGA (n = 3994), and ~36wkGA (n = 3780). Samples were analysed using clinical grade Roche Elecsys immunoassays on an e411 platform (Roche). The red lines indicate the 50th percentile values and the black lines represent the 5th and 95th percentile values at 12, 20, 28 and 36 completed weeks of GA ± 2 weeks difference.
the matched blood samples. This broad approach has previously yielded novel markers. Using older expression array-based technology, it was discovered that excess placental production of sFlt1 contributes to increased maternal circulating sFlt-1 in pregnancies complicated by PE [41]. Circulating sFlt-1 measurements, combined with PlGF levels, have been shown to be useful in the assessment of PE. High sFlt-1 concentrations and increased sFlt-1:PlGF ratio have been measured in women who later developed PE five weeks before the clinical onset of the disease [42,43]. The same authors reported that a high sFlt-1:PlGF ratio is highly predictive of PE when tested in combination with soluble endoglin levels. Moreover, sFlt-1:PlGF ratio has now been shown to be clinically useful in ruling out preeclampsia within one week after the test when the condition is suspected [44].

In the POP study, a total of 320 placental samples (from 55 matched severe SGA [<5th percentile]/appropriate for gestational age (AGA) pairs, and 105 matched PE/control pairs) have been studied using RNA-Seq analysis of both long RNAs (i.e., totRNA-seq identifying mRNAs and lncRNAs) and small RNAs (i.e., smallRNA-seq identifying miRNAs and piRNAs). This work has generated large volumes of data. For example, in the projects based on totRNA-Seq, we have an average of 102 million reads (125 base pair long, single end) per sample, resulting in a total of ~33 billion reads. The differentially expressed RNAs or the corresponding coded proteins, in case of altered mRNAs, will be later studied in the maternal circulation. In these NGS-based projects, information derived from the clinical records and outcome data collected in the POP study were used not only to identify and characterise disease subtypes, but also to carefully match cases and controls (e.g., according to GA, maternal BMI and age, smoking, fetal sex, labour, and mode of delivery). The nested case-control design has a higher statistical power than unmatched designs and it accounts for confounding through matching, as described above. Interestingly, the initial analysis of the results from the SGA/AGA pairs revealed that the accurate definition of clinical subgroups of SGA (i.e., small healthy babies or small babies with poor AC growth velocity, SGA pregnancies with high resistance umbilical Doppler, high resistance uterine Doppler, low maternal PAPP-A, or maternal hypertension) led to the identification of a higher number of differentially expressed RNAs compared to an analysis including all the SGA samples. This finding illustrates the importance of deep phenotyping of cases when the outcome can be the end point of multiple different pathological processes.

4. Conclusions

Careful design of a large prospective study involves accurate collection and storage of clinical information, outcome data and biological samples (Fig. 4). Clinical information helps defining the biological samples and, likewise, the results obtained from the
biological samples contribute to accurate phenotyping of the patient and the pregnancy. Moreover, such a design allows the identification of clinically useful biomarker candidates. These considerations need to be taken into account when designing a study ultimately aiming at improving management of patients and pregnancy outcomes.

Conflict of interest statement

G.C.S. receives/has received research support from GE (supply of two diagnostic ultrasound systems used in the current study). Other commercial interests for G.C.S. are as follows: support from Roche (supply of equipment and reagents for biomarker studies, ~£600,000 in value) and from GlaxoSmithKline (GSK) (~£200,000) for a project to study effects of retosiban in human myometrium, payment to attend advisory boards by GSK and Roche, and payment for consultant work for GSK. G.C.S. is named inventor in a patent submitted by GSK (U.K.) for novel application of an existing GSK compound for the prevention of preterm birth (PCT/EP2014/062602). No other potential conflicts of interest relevant to this article were reported.

Acknowledgements

This study was funded by the NIHR Cambridge Comprehensive Biomedical Research Centre [grant number A019057], the Medical Research Council [grant number MR/K021133/1] and the Stillbirth and Neonatal Death Society (SANDS). We would like to thank all the participants in the POP study. We are extremely grateful to the research technicians involved in the POP study for making the samples collection possible and for their help with the ongoing projects.

References


